Benefits
Selected reproductive/endocrine indications; the label explicitly rejects claims of effectiveness for obesity.
Named U.S. presentation only; selected label sections.
Peptide library
HCG
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. The selected PREGNYL label does not supply a numerical human elimination half-life. Hormonal effects and data for recombinant chorionic gonadotropin cannot substitute for a matched estimate for this urinary-derived product. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
About this assessment
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Who was studied
The population specified by this product label; other indications and jurisdictions remain outside this check.
What the sources found
Selected reproductive/endocrine indications; the label explicitly rejects claims of effectiveness for obesity.
Regulatory scope
U.S. label record for BLA017692. This does not confer authorization on other products using the ingredient name.
What remains unknown
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
How it works
PREGNYL chorionic gonadotropin, 10,000 USP-unit multidose vial
Consult the product label for pharmacology. A mechanism does not extend its approved indications.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Reported adverse effects
- Fertility treatment requires ovarian-response monitoring and assessment of hypersensitivity and hyperstimulation risks.
Named U.S. presentation only; selected label sections.
Contraindications
- PREGNYL: gonadotropin/excipient hypersensitivity; primary ovarian failure; uncontrolled thyroid/adrenal/pituitary disorders; specified hormone-dependent or hypothalamic/pituitary tumors; reproductive malformations or fibroids incompatible with pregnancy; unexplained vaginal bleeding.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Sources used for this snapshot
Claim-by-claim evidence
Adverseeffects
Fertility treatment requires ovarian-response monitoring and assessment of hypersensitivity and hyperstimulation risks.
Named U.S. presentation only; selected label sections.
Storage
PREGNYL: unopened 15–30°C; after reconstitution refrigerate 2–8°C and discard after 60 days. Do not shake or freeze.
Named U.S. presentation only; selected label sections.
Pharmacokinetics
The selected PREGNYL label does not supply a numerical human elimination half-life. Hormonal effects and data for recombinant chorionic gonadotropin cannot substitute for a matched estimate for this urinary-derived product.
Named U.S. product only; label revision 20240218. Educational extraction, not complete clinical review.
Contraindications
PREGNYL: gonadotropin/excipient hypersensitivity; primary ovarian failure; uncontrolled thyroid/adrenal/pituitary disorders; specified hormone-dependent or hypothalamic/pituitary tumors; reproductive malformations or fibroids incompatible with pregnancy; unexplained vaginal bleeding.
Named U.S. product only; label revision 20240218. Educational extraction, not complete clinical review.
References
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. 2005.
PMID: 15713727
PREGNYL chorionic gonadotropin, 10,000 USP-unit multidose vial. U.S. structured product label, effective 20240218. Selected sections only.
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.